BRAF and melanoma: Here, we exploit matched patient-derived melanoma cell lines from treatment-naive, treatment-sensitive, and NRASQ61K-based resistant tumor states established from patient-derived tumor xenografts to study BRAF-resistance-driven alterations in kinase activation states (Figure 3A) (Kemper et al., 2015).